LMR Partners’s AgomAb Therapeutics NV AGMB Stock Holding History

LMR Partners’s Portfolio AGMB Stock Details AGMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$3.15M	–	1910
2026 Q1	$3.15M	Buy	+300,000	New	+$4.25M	0.01%	765

Other funds holding AGMB

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Federated Hermes

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Andera Partners Paris $206M AUM

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LMR Partners's AGMB Position: Q2 2026 in Review

LMR Partners sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 300,000 shares — an estimated $3.15M sold.

LMR Partners first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $3.15M in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

LMR Partners reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 300,000 AgomAb Therapeutics NV shares in Q2 2026, an estimated $3.15M.
LMR Partners first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
LMR Partners's AgomAb Therapeutics NV position peaked at $3.15M in Q1 2026.
34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.